(Q46148243)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

25 October 2022

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

author name string

Zehua Sun

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Lixin Yan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jiansong Tang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Qian Qian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jerica Lenberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Dandan Zhu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Wan Liu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Yilin Wang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Shiqiang Lu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

publication date

16 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

2 January 2018

1 reference

25 October 2022

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

25 October 2022

243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

75-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

Ammonium ions improve the survival of glutamine-starved hybridoma cells

7 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Development of a new yeast surface display system based on Spi1 as an anchor protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Improved efficiency of EBV transformation of B-lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Single cell sorting and cloning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Isolation of human monoclonal antibodies by mammalian cell display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Hybridoma cell-culture and glycan profile dataset at various bioreactor conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Engineering antibodies by yeast display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Production of LacZ inducible T cell hybridoma specific for human and mouse gp100₂₅₋₃₃ peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Human recombinant antibodies specific for hepatitis C virus core and envelope E2 peptides from an immune phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Antibody humanization by structure-based computational protein design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Fluorescent protein-tagged Vpr dissociates from HIV-1 core after viral fusion and rapidly enters the cell nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Generation of Immunity against Pathogens via Single-Domain Antibody-Antigen Constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Measuring T Cell-to-T Cell HIV-1 Transfer, Viral Fusion, and Infection Using Flow Cytometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Assurance of monoclonality in one round of cloning through cell sorting for single cell deposition coupled with high resolution cell imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Phage Display: A Powerful Technology for the Generation of High-Specificity Affinity Reagents from Alternative Immune Sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Protein selection using yeast surface display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Specific determination of influenza H7N2 virus based on biotinylated single-domain antibody from a phage-displayed library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a lung cancer patient with paraneoplastic encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Simian immunodeficiency virus infection evades vaccine-elicited antibody responses to V2 region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

The quest for an antibody-based HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Evolution of B cell analysis and Env trimer redesign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Impact on monoclonal antibody production in murine hybridoma cell cultures of adenosine receptor antagonists and phosphodiesterase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Versatility of using major histocompatibility complex class II dextramers for derivation and characterization of antigen-specific, autoreactive T cell hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Corrigendum: Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Human antibodies for immunotherapy development generated via a human B cell hybridoma technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A Rapid Method to Characterize Mouse IgG Antibodies and Isolate Native Antigen Binding IgG B Cell Hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Effect of human adenovirus on antibody-dependent cellular cytotoxicity (ADCC) in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Extracting human antibody sequences from public databases for antibody humanization: high frequency of species assignment errors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Enhanced monoclonal antibody production in hybridoma cells by LPS and Anti-mIgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification and specificity of broadly neutralizing antibodies against HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Application of modified yeast surface display technologies for non-Antibody protein engineering.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Requirement of calmodulin binding by HIV-1 gp160 for enhanced FAS-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

The hybridoma revolution: an offshoot of basic research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Tabhu: tools for antibody humanization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Generation and Characterization of a Novel Fusion Partner Cell Line for the Production of Human Macrophage Hybridoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Use of broadly neutralizing antibodies for HIV-1 prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Immunogenomic engineering of a plug-and-(dis)play hybridoma platform.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Evolution of phage display technology: from discovery to application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Humanized Anti-IL-5 Antibody Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Antibody humanization methods - a review and update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-specific B cell response in patients with broadly neutralizing serum activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

7 January 2021

Phage and Yeast Display

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Mammalian Cell Surface Display as a Novel Method for Developing Engineered Lectins with Novel Characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Quantification of antibody production of individual hybridoma cells by surface plasmon resonance imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Two human immunodeficiency virus Type 2 cases in US blood donors including serologic, molecular, and genomic characterization of an epidemiologically unusual case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Use of HCA in subproteome-immunization and screening of hybridoma supernatants to define distinct antibody binding patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A rapid screening and production method using a novel mammalian cell display to isolate human monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Hybridoma technologies for antibody production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Directed Evolution of Protein Thermal Stability Using Yeast Surface Display.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Humanization of a chicken anti-IL-12 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

The HIV-1 envelope glycoprotein structure: nailing down a moving target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

7 January 2021

inferred from DOI database lookup

Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.10.011

7 January 2021

inferred from DOI database lookup

Antibody immunoprophylaxis and immunotherapy for influenza virus infection: utilization of monoclonal or polyclonal antibodies?

1 reference

12 December 2020

The hybridoma revolution: an offshoot of basic research

1 reference

12 December 2020

EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).

1 reference

12 December 2020

Effect of medium composition on hybridoma growth and antibody production.

1 reference

12 December 2020

Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant

1 reference

12 December 2020

Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin

1 reference

12 December 2020

Immortalization of EBV-infected B cells is not influenced by exogenous signals acting on B cell proliferation. Effects of mutant EL-4 thymoma cells and transforming growth factor-beta.

1 reference

12 December 2020

10.1016/J.VIRUSRES.2017.10.011

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29051051%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

PubMed publication ID

29051051

1 reference